Life Sciences IPOs Take a Breather December 02, 2013 | Press Release
Booming IPO Market Improving M&A Terms for Private Biotechs November 01, 2013 | Press Release
ADMA Biologics, Inc. Announces Pricing October 18, 2013 | Press ReleaseSee all News
G. Steven Burrill
Chief Executive Officer
Brazil has emerged in recent years as one of the prime investment locations in Emerging Market countries. Its consistent economic growth and increasingly favorable business environment have contributed to the creation of a wealth of investment opportunities.
In addition, the Brazilian government has set an improved legal framework for business models based on innovation and proprietary products as well as crafted legislation that provides the sharing of intellectual property and other resources between public and private entities, allowing direct support for R&D activities in private enterprises. These initiatives not only promote technological innovation but also act as incentives to boost overall R&D spending, the life blood of the life sciences industry.
Technological and healthcare accomplishments in Brazil have achieved global competitiveness status and, in line with global trends, the country has established a strong world presence in a number of areas of life sciences R&D, such as: Genomics, Stem Cell Research, Vaccines, Neurosciences, Biofuels and Green Biotechnology. Moreover, with strong support from the Brazilian government, Brazil’s biotechnology and pharmaceutical industry is currently the largest complex in Latin American, with more than $17 billion in revenues in 2008.
Burrill & Company will play an important role to support Brazil enter the world stage of biotechnology at a unique time when the intersection of Brazil’s comparative advantages in human capital, science and technology assets, biological diversity, and other natural resources, are leveraged by global circumstances.
The Burrill Brazil operation is headed by Joao Paulo V. Poiares Baptista, Managing Director, from our office in Rio de Janeiro, Brazil.
Recently we established two investment funds within the region: the Burrill Brazil Fund and the Burrill Chile Life Sciences Fund.
Burrill Brazil Fund I
The Burrill Brasil I, is a Brazil based life sciences Investment Fund with the purpose of long-term capital appreciation through venture capital, private equity and structured equity-related investments in life sciences companies, including biopharmaceutical, pharmaceutical, medical devices, diagnostic, health & wellness, health care services and delivery, agricultural biotechnology, industrial biotechnology, renewable chemicals and renewable biofuel companies located within or strategic to Brazil. The Burrill Brazil Fund strategy is to be diversified as to stage of investment and life sciences sub-sector. Upon its closure by September 2010, this fund shall have a minimum committed capital of $150 million, and a 10 year length.
Burrill Brazil – Latin America Headquarters
R. Vinícius de Morais, 111, 3º Andar, Ipanema
Rio de Janeiro - CEP 22411-010 - RJ
Phone: (55) (21) 3988 9620